CHAPEL HILL, N.C., Feb 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc.
(Nasdaq: POZN), a pharmaceutical development company with a portfolio of product
candidates for the treatment of migraine, announced that John R. Plachetka,
Pharm.D., the company's chairman, president and chief executive officer, will
make a presentation to investors during the BIO CEO & Investor Conference. The
presentation is scheduled for Thursday, February 21, 2002 at 8:50 a.m. EST at
the Waldorf Astoria in New York City. The presentation will also be broadcast
live through the Internet and will remain archived for 30 days. The webcast can
be accessed through the POZEN website with the following URL:
North Carolina-based POZEN Inc. is a pharmaceutical development company
committed to building a portfolio of products with significant commercial
potential in select therapeutic areas. POZEN's initial focus is on developing
products for migraine therapy, a global market expected to exceed $2.6 billion
this year. The company's common stock is traded on The Nasdaq Stock Market under
the symbol "POZN."
POZEN is on the Internet at www.pozen.com .
Chief Financial Officer, of POZEN
Kathy Brunson of FRB Weber Shandwick